

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/071,174	02/07/2002	John C. Reed	8014-014 US	2991
CATALYST L 9710 SCRANT	7590 05/22/200 AW GROUP, APC ON ROAD, SUITE S-1		EXAMINER ANGELL, JON E	
SAN DIEGO, CA 92121			ART UNIT	PAPER NUMBER
			1635	
			·	
			MAIL DATE	DELIVERY MODE
			05/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/071,174	REED ET AL.	
Examiner	Art Unit	
J. Eric Angell	1635	

	J. Eric Angell	1635	
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address	
 THE REPLY FILED <u>30 April 2007</u> FAILS TO PLACE THIS APF			
The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follor places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	n the same day as filing a Notice of wing replies: (1) an amendment, at otice of Appeal (with appeal fee) in	f Appeal. To avoid abandonment of ffidavit, or other evidence, which compliance with 37 CFR 41.31; or (3)	
a) The period for reply expires 5 months from the mailing date b) The period for reply expires on: (1) the mailing date of this a no event, however, will the statutory period for reply expire Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN TH 106.07(f).	ng date of the final rejection. IE FIRST REPLY WAS FILED WITHIN	ì
Extensions of time may be obtained under 37 CFR 1.136(a). The date nave been filed is the date for purposes of determining the period of example of CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orion to than three months after the mailing do	t of the fee. The appropriate extension fee ginally set in the final Office action; or (2) as	S
The Notice of Appeal was filed on A brief in com filing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed AMENDMENTS	ension thereof (37 CFR 41.37(e)), t	to avoid dismissal of the appeal. Since	
The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below.)	onsideration and/or search (see NC ow);	OTE below);	
(c) They are not deemed to place the application in be appeal; and/or			
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a))			
 The amendments are not in compliance with 37 CFR 1. Applicant's reply has overcome the following rejection(s 		ompliant Amendment (PTOL-324).	
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 			;
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:	☐ will not be entered, or b) ☒ wovided below or appended.	ill be entered and an explanation of	
Claim(s) allowed: <u>1,4-9,11-15,17-23,25-28 and 142-163</u> . Claim(s) objected to:			
Claim(s) rejected: <u>16,76 and 77</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
3. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar was not earlier presented. See 37 CFR 1.116(e).	ut before or on the date of filing a h nd sufficient reasons why the affida	Notice of Appeal will <u>not</u> be entered wit or other evidence is necessary and	i
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessa	overcome all rejections under appe	eal and/or appellant fails to provide a	
10. The affidavit or other evidence is entered. An explanation of the consideration of the co	on of the status of the claims after	entry is below or attached.	
 The request for reconsideration has been considered b <u>See Continuation Sheet.</u> 	ut does NOT place the application	in condition for allowance because:	
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s)		
		/J. E. Angell/ Primary Examiner, AU 1635	

Continuation of 5. Applicant's reply has overcome the following rejection(s): 35 U.S.C. 112, first paragraph (New Matter) as it applies to claim 15, 17-23, 25.

Continuation of 11. does NOT place the application in condition for allowance because: Applicants argue that In re Wertheim is the apropriate case for guidance relative to inventive claims within disclosed ranges. In response, it is noted that in the decision in In re Wertheim, (541 F.2d 257, 191 USPQ 90 (CCPA 1976)), the ranges described in the original specification included a range of "25%-60%" and specific examples of "36%" and "50%." A corresponding new claim limitation to "at least 35%" did not meet the description requirement because the phrase "at least" had no upper limit and caused the claim to read literally on embodiments outside the "25% to 60%" range, however a limitation to "between 35% and 60%" did meet the description requirement. In the instant case, claim 76 encompasses a nucleic acid greater than 700 base pairs in length. Like Wertheim, this does not meet the descritpion requirement because the phrase " greater than 700 base pairs" has no upper limit, and is thus, necessarily outside the range(s) disclosed in the specification. Furthermore, the explicit disclosure of "36%" and the range 25%-60% was considered sufficient disclosure to support the new range "BETWEEN 35% and 60%" (emphasis added). This is different from the instant case where the claims encompass nucleic acid sequences 701-1000 base pairs in length (claim 16), and nucleic acid sequences greater than 700 base pairs in length and where the specification does not disclose any nucleic acid that are anywhere approxiamtely near 700 or 701 base pairs, as is the case in Wertheim where the range 25-60% and the specific embodiment of 36% was sufficiently identify. Therefore, as in the case of In re Ruschig, this specific embodiment within the scope of the disclosure, but not particularly identified in the specification, is considered new matter.

/J. E. Angell/ Primary Examiner, AU 1635